Sunshine Lake Pharma Co., Ltd.: Phase 1 study started recruiting, 110 planned (Advanced Malignant Solid Tumors)
Sunshine Lake Pharma Co., Ltd.: Phase 1 study started recruiting, 110 planned (Advanced Malignant Solid Tumors). Its enrollment of 110 is above the median of 80 (62nd percentile). Dated 41 days ago, it serves as a historical benchmark. Score 65/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 110 · 62th percentile of 8,879 ClinicalTrialStartPulse records · 1.4x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors |
| NCT ID | NCT07824934 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Advanced Malignant Solid Tumors |
| Intervention types | drug |
| Target enrollment | 110 |
| Site countries | China |
| Posted | 2026-09-17 |
| Planned start | 2026-09-18 |
| Event | Started recruiting |
| Event date | 2026-09-18 |
| Last update posted | 2026-09-24 |
| enrollment percentile | 62th of 8,879 (median 80, 1.4x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Sunshine Lake Pharma Co., Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Sunshine Lake Pharma Co. + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-09-24
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Sunshine Lake Pharma Co., Ltd. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Sunshine Lake Pharma Co., Ltd.'s enrollment: 62nd percentile of 8,879 records
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
65 / 100 Score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- 110 participants planned.
What is the ClinicalTrialStartPulse record for Sunshine Lake Pharma Co., Ltd.?
Sunshine Lake Pharma Co., Ltd.'s Phase 1 study (NCT07824934) in Advanced Malignant Solid Tumors, first posted 2026-09-17: started recruiting (2026-09-18), in an update posted 2026-09-24.
How does Sunshine Lake Pharma Co., Ltd. compare to other ClinicalTrialStartPulse records?
Its enrollment of 110 sits in the upper half (62th percentile) of 8,879 records; the median is 80. It is 41 days old, still within a typical 45-day follow-up window.
Sunshine Lake Pharma Co., Ltd. vs. top 2 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | NONUS | 110 | 62nd | 2026-09-24 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | NONUS | 270 | 81st | 2026-11-03 |
| Mabsoft Therapeutics (Shanghai) Co., Ltd. | NONUS | 420 | 88th | 2026-10-28 |
Related records
- Hoffmann-La Roche
- MacroGenics
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
- Sutro Biopharma, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Genentech, Inc.
ClinicalTrialStartPulse: Phase 1 ClinicalTrialStartPulse: Outside the US only
How to monitor Sunshine Lake Pharma Co., Ltd. and peer phase 1 records
Get new ClinicalTrialStartPulse records like Sunshine Lake Pharma Co., Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.